Elanco Animal Health Incorporated [NYSE: ELAN] loss -1.70% or -0.62 points to close at $35.80 with a heavy trading volume of 3288593 shares. The company report on August 2, 2021 that TriRx Completes Acquisition of Elanco Animal Health Facility in Shawnee, Kansas.
TriRx Pharmaceutical Services, LLC, a leading international CDMO, announced that it has finalized and closed on an agreement with Elanco Animal Health Incorporated (NYSE:ELAN) to acquire the ownership and operations of its manufacturing site in Shawnee, Kansas. Elanco is a global animal health leader dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The two companies also entered into a long-term supply agreement for this site.
Timothy C. Tyson, Chairman & CEO of TriRx, stated, “We are excited to complete the transaction to acquire the Shawnee facility and look forward to continuing to build on the strategic partnership between Elanco, TriRx, the workforce, and the local community in Shawnee, Kansas. TriRx will transition the Elanco Center of Manufacturing Excellence to a Global Center of Excellence serving the pharmaceutical contract development and manufacturing market.”.
It opened the trading session at $36.42, the shares rose to $36.50 and dropped to $35.30, the range by which the price of stock traded the whole day. The daily chart for ELAN points out that the company has recorded 23.32% gains over the past six months. However, it is still -50.42% lower than its most recent low trading price.
If we look at the average trading volume of 3.28M shares, ELAN reached to a volume of 3288593 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Elanco Animal Health Incorporated [ELAN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ELAN shares is $35.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ELAN stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Credit Suisse have made an estimate for Elanco Animal Health Incorporated shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 05, 2021. The new note on the price target was released on June 15, 2021, representing the official price target for Elanco Animal Health Incorporated stock. On May 11, 2021, analysts increased their price target for ELAN shares from 25 to 29.
The Average True Range (ATR) for Elanco Animal Health Incorporated is set at 0.74, with the Price to Sales ratio for ELAN stock in the period of the last 12 months amounting to 4.41. The Price to Book ratio for the last quarter was 2.18, with the Price to Cash per share for the same quarter was set at 1.08.
Trading performance analysis for ELAN stock
Elanco Animal Health Incorporated [ELAN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.21. With this latest performance, ELAN shares gained by 3.59% in over the last four-week period, additionally plugging by 23.32% over the last 6 months – not to mention a rise of 41.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ELAN stock in for the last two-week period is set at 52.24, with the RSI for the last a single of trading hit 47.83, and the three-weeks RSI is set at 54.04 for Elanco Animal Health Incorporated [ELAN]. The present Moving Average for the last 50 days of trading for this stock 35.13, while it was recorded at 36.38 for the last single week of trading, and 31.95 for the last 200 days.
Elanco Animal Health Incorporated [ELAN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Elanco Animal Health Incorporated [ELAN] shares currently have an operating margin of -2.35 and a Gross Margin at +38.09. Elanco Animal Health Incorporated’s Net Margin is presently recorded at -17.11.
Return on Total Capital for ELAN is now -0.67, given the latest momentum, and Return on Invested Capital for the company is -5.06. Return on Equity for this stock declined to -7.99, with Return on Assets sitting at -4.20. When it comes to the capital structure of this company, Elanco Animal Health Incorporated [ELAN] has a Total Debt to Total Equity ratio set at 74.51. Additionally, ELAN Total Debt to Total Capital is recorded at 42.70, with Total Debt to Total Assets ending up at 35.69. Long-Term Debt to Equity for the company is recorded at 67.53, with the Long-Term Debt to Total Capital now at 38.70.
Reflecting on the efficiency of the workforce at the company, Elanco Animal Health Incorporated [ELAN] managed to generate an average of -$59,585 per employee. Receivables Turnover for the company is 3.33 with a Total Asset Turnover recorded at a value of 0.25.Elanco Animal Health Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.60.
Elanco Animal Health Incorporated [ELAN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ELAN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Elanco Animal Health Incorporated go to 11.00%.
An analysis of insider ownership at Elanco Animal Health Incorporated [ELAN]
There are presently around $17,068 million, in the hands of institutional investors. The top three institutional holders of ELAN stocks are: VANGUARD GROUP INC with ownership of 42,146,299, which is approximately 0.993% of the company’s market cap and around 0.20% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 41,773,539 shares of the stock with an approximate value of $1.5 billion in ELAN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $1.13 billion in ELAN stock with ownership of nearly -2.976% of the company’s market capitalization.
Positions in Elanco Animal Health Incorporated stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 246 institutional holders increased their position in Elanco Animal Health Incorporated [NYSE:ELAN] by around 55,862,015 shares. Additionally, 182 investors decreased positions by around 33,081,001 shares, while 85 investors held positions by with 387,823,020 shares. The mentioned changes placed institutional holdings at 476,766,036 shares, according to the latest SEC report filing. ELAN stock had 77 new institutional investments in for a total of 13,448,773 shares, while 60 institutional investors sold positions of 8,125,829 shares during the same period.